HEADER TRANSLATION 19-MAY-23 8SX4 TITLE CRYSTAL STRUCTURE OF EIF4E IN COMPLEX WITH COMPOUND 7N COMPND MOL_ID: 1; COMPND 2 MOLECULE: EUKARYOTIC TRANSLATION INITIATION FACTOR 4E; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: EIF4E,EIF-4F 25 KDA SUBUNIT,MRNA CAP-BINDING PROTEIN; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: EIF4E, EIF4EL1, EIF4F; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS EIF4E, TRANSLATION INITIATION INHIBITOR, TRANSLATION EXPDTA X-RAY DIFFRACTION AUTHOR J.L.MEAGHER,J.A.STUCKEY REVDAT 2 23-AUG-23 8SX4 1 JRNL REVDAT 1 21-JUN-23 8SX4 0 JRNL AUTH E.L.CARDENAS,R.L.O'ROURKE,A.MENON,J.MEAGHER,J.STUCKEY, JRNL AUTH 2 A.L.GARNER JRNL TITL DESIGN OF CELL-PERMEABLE INHIBITORS OF EUKARYOTIC JRNL TITL 2 TRANSLATION INITIATION FACTOR 4E (EIF4E) FOR INHIBITING JRNL TITL 3 ABERRANT CAP-DEPENDENT TRANSLATION IN CANCER. JRNL REF J.MED.CHEM. V. 66 10734 2023 JRNL REFN ISSN 0022-2623 JRNL PMID 37471629 JRNL DOI 10.1021/ACS.JMEDCHEM.3C00917 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH E.L.CARDENAS,R.L.O'ROURKE,A.MENON,J.MEAGHER,J.STUCKEY, REMARK 1 AUTH 2 A.L.GARNER REMARK 1 TITL DESIGN OF CELL-PERMEABLE INHIBITORS OF EUKARYOTIC REMARK 1 TITL 2 TRANSLATION INITIATION FACTOR 4E (EIF4E) FOR INHIBITING REMARK 1 TITL 3 ABERRANT CAP-DEPENDENT TRANSLATION IN CANCER. REMARK 1 REF BIORXIV 2023 REMARK 1 REFN ISSN 2692-8205 REMARK 1 PMID 37292917 REMARK 1 DOI 10.1101/2023.05.23.541912 REMARK 2 REMARK 2 RESOLUTION. 1.99 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.10.4 (17-FEB-2023) REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.99 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 37.81 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 95.9 REMARK 3 NUMBER OF REFLECTIONS : 24565 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.200 REMARK 3 R VALUE (WORKING SET) : 0.197 REMARK 3 FREE R VALUE : 0.243 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.330 REMARK 3 FREE R VALUE TEST SET COUNT : 1310 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 51 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.99 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.01 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 64.21 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 492 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2238 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 468 REMARK 3 BIN R VALUE (WORKING SET) : 0.2219 REMARK 3 BIN FREE R VALUE : 0.2585 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.88 REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2990 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 59 REMARK 3 SOLVENT ATOMS : 162 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 26.48 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.15200 REMARK 3 B22 (A**2) : -0.04420 REMARK 3 B33 (A**2) : -0.10780 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -1.08300 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.230 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.206 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.174 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.208 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.176 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.935 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.909 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 3129 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 4245 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1093 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : 559 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 3129 ; 10.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 387 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 2532 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 0.87 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.34 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 16.10 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 8SX4 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 22-MAY-23. REMARK 100 THE DEPOSITION ID IS D_1000274629. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 26-JUL-22 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 21-ID-D REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.1276 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER X 9M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 24897 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.986 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.0 REMARK 200 DATA REDUNDANCY : 5.200 REMARK 200 R MERGE (I) : 0.07400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 10.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.03 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.2 REMARK 200 DATA REDUNDANCY IN SHELL : 4.20 REMARK 200 R MERGE FOR SHELL (I) : 0.38300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASES REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 41.65 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.11 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 16-26% PEG 3350, 0.1 M MES PH 6.0, 10% REMARK 280 ISOPROPANOL AND 2 MM CACL2, VAPOR DIFFUSION, SITTING DROP, REMARK 280 TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 37.16400 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 27 REMARK 465 VAL A 28 REMARK 465 ALA A 29 REMARK 465 ASN A 30 REMARK 465 PRO A 31 REMARK 465 GLU A 32 REMARK 465 SER A 83 REMARK 465 ASN A 84 REMARK 465 LEU A 85 REMARK 465 MET A 86 REMARK 465 PRO A 87 REMARK 465 GLY A 208 REMARK 465 SER A 209 REMARK 465 THR A 210 REMARK 465 THR A 211 REMARK 465 MET B 27 REMARK 465 VAL B 28 REMARK 465 ALA B 29 REMARK 465 GLY B 208 REMARK 465 SER B 209 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ILE A 35 CG1 CG2 CD1 REMARK 470 ASN B 30 CG OD1 ND2 REMARK 470 LYS B 52 CG CD CE NZ REMARK 470 MET B 86 CG SD CE REMARK 470 LYS B 206 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 50 108.19 -50.95 REMARK 500 ASP A 67 21.78 -147.33 REMARK 500 ASP A 143 -130.53 53.56 REMARK 500 ASP B 51 99.83 -172.04 REMARK 500 ASP B 143 -115.51 48.45 REMARK 500 REMARK 500 REMARK: NULL DBREF 8SX4 A 28 217 UNP P06730 IF4E_HUMAN 28 217 DBREF 8SX4 B 28 217 UNP P06730 IF4E_HUMAN 28 217 SEQADV 8SX4 MET A 27 UNP P06730 INITIATING METHIONINE SEQADV 8SX4 MET B 27 UNP P06730 INITIATING METHIONINE SEQRES 1 A 191 MET VAL ALA ASN PRO GLU HIS TYR ILE LYS HIS PRO LEU SEQRES 2 A 191 GLN ASN ARG TRP ALA LEU TRP PHE PHE LYS ASN ASP LYS SEQRES 3 A 191 SER LYS THR TRP GLN ALA ASN LEU ARG LEU ILE SER LYS SEQRES 4 A 191 PHE ASP THR VAL GLU ASP PHE TRP ALA LEU TYR ASN HIS SEQRES 5 A 191 ILE GLN LEU SER SER ASN LEU MET PRO GLY CYS ASP TYR SEQRES 6 A 191 SER LEU PHE LYS ASP GLY ILE GLU PRO MET TRP GLU ASP SEQRES 7 A 191 GLU LYS ASN LYS ARG GLY GLY ARG TRP LEU ILE THR LEU SEQRES 8 A 191 ASN LYS GLN GLN ARG ARG SER ASP LEU ASP ARG PHE TRP SEQRES 9 A 191 LEU GLU THR LEU LEU CYS LEU ILE GLY GLU SER PHE ASP SEQRES 10 A 191 ASP TYR SER ASP ASP VAL CYS GLY ALA VAL VAL ASN VAL SEQRES 11 A 191 ARG ALA LYS GLY ASP LYS ILE ALA ILE TRP THR THR GLU SEQRES 12 A 191 CYS GLU ASN ARG GLU ALA VAL THR HIS ILE GLY ARG VAL SEQRES 13 A 191 TYR LYS GLU ARG LEU GLY LEU PRO PRO LYS ILE VAL ILE SEQRES 14 A 191 GLY TYR GLN SER HIS ALA ASP THR ALA THR LYS SER GLY SEQRES 15 A 191 SER THR THR LYS ASN ARG PHE VAL VAL SEQRES 1 B 191 MET VAL ALA ASN PRO GLU HIS TYR ILE LYS HIS PRO LEU SEQRES 2 B 191 GLN ASN ARG TRP ALA LEU TRP PHE PHE LYS ASN ASP LYS SEQRES 3 B 191 SER LYS THR TRP GLN ALA ASN LEU ARG LEU ILE SER LYS SEQRES 4 B 191 PHE ASP THR VAL GLU ASP PHE TRP ALA LEU TYR ASN HIS SEQRES 5 B 191 ILE GLN LEU SER SER ASN LEU MET PRO GLY CYS ASP TYR SEQRES 6 B 191 SER LEU PHE LYS ASP GLY ILE GLU PRO MET TRP GLU ASP SEQRES 7 B 191 GLU LYS ASN LYS ARG GLY GLY ARG TRP LEU ILE THR LEU SEQRES 8 B 191 ASN LYS GLN GLN ARG ARG SER ASP LEU ASP ARG PHE TRP SEQRES 9 B 191 LEU GLU THR LEU LEU CYS LEU ILE GLY GLU SER PHE ASP SEQRES 10 B 191 ASP TYR SER ASP ASP VAL CYS GLY ALA VAL VAL ASN VAL SEQRES 11 B 191 ARG ALA LYS GLY ASP LYS ILE ALA ILE TRP THR THR GLU SEQRES 12 B 191 CYS GLU ASN ARG GLU ALA VAL THR HIS ILE GLY ARG VAL SEQRES 13 B 191 TYR LYS GLU ARG LEU GLY LEU PRO PRO LYS ILE VAL ILE SEQRES 14 B 191 GLY TYR GLN SER HIS ALA ASP THR ALA THR LYS SER GLY SEQRES 15 B 191 SER THR THR LYS ASN ARG PHE VAL VAL HET WXL A 301 30 HET M7G B 301 29 HETNAM WXL [(~{Z})-4-[2-AZANYL-7-[(5-CHLORANYL-1~{H}-INDOL-2-YL) HETNAM 2 WXL METHYL]-6-OXIDANYLIDENE-1~{H}-PURIN-9-YL]BUT-2- HETNAM 3 WXL ENYL]PHOSPHONIC ACID HETNAM M7G 7N-METHYL-8-HYDROGUANOSINE-5'-DIPHOSPHATE FORMUL 3 WXL C18 H19 CL N6 O4 P 1+ FORMUL 4 M7G C11 H19 N5 O11 P2 FORMUL 5 HOH *162(H2 O) HELIX 1 AA1 THR A 55 ALA A 58 5 4 HELIX 2 AA2 VAL A 69 LEU A 81 1 13 HELIX 3 AA3 GLN A 120 ASP A 125 1 6 HELIX 4 AA4 ASP A 125 GLY A 139 1 15 HELIX 5 AA5 PHE A 142 ASP A 147 5 6 HELIX 6 AA6 ASN A 172 LEU A 187 1 16 HELIX 7 AA7 HIS A 200 THR A 205 1 6 HELIX 8 AA8 THR B 55 ALA B 58 5 4 HELIX 9 AA9 VAL B 69 ILE B 79 1 11 HELIX 10 AB1 LEU B 81 LEU B 85 5 5 HELIX 11 AB2 GLN B 120 ASP B 125 1 6 HELIX 12 AB3 ASP B 125 GLY B 139 1 15 HELIX 13 AB4 PHE B 142 ASP B 147 5 6 HELIX 14 AB5 ASN B 172 GLY B 188 1 17 HELIX 15 AB6 HIS B 200 ALA B 204 1 5 SHEET 1 AA1 8 LEU A 60 THR A 68 0 SHEET 2 AA1 8 PRO A 38 PHE A 48 -1 N TRP A 43 O PHE A 66 SHEET 3 AA1 8 ASP A 90 LYS A 95 -1 O PHE A 94 N ALA A 44 SHEET 4 AA1 8 VAL A 149 ASN A 155 -1 O CYS A 150 N LYS A 95 SHEET 5 AA1 8 LYS A 162 THR A 167 -1 O TRP A 166 N CYS A 150 SHEET 6 AA1 8 GLY A 111 THR A 116 -1 N GLY A 111 O THR A 167 SHEET 7 AA1 8 GLY A 196 SER A 199 -1 O GLY A 196 N LEU A 114 SHEET 8 AA1 8 PHE A 215 VAL A 216 -1 O PHE A 215 N TYR A 197 SHEET 1 AA2 8 LEU B 60 THR B 68 0 SHEET 2 AA2 8 PRO B 38 PHE B 48 -1 N LEU B 45 O SER B 64 SHEET 3 AA2 8 ASP B 90 LYS B 95 -1 O SER B 92 N TRP B 46 SHEET 4 AA2 8 VAL B 149 ASN B 155 -1 O VAL B 154 N TYR B 91 SHEET 5 AA2 8 LYS B 162 THR B 167 -1 O TRP B 166 N CYS B 150 SHEET 6 AA2 8 GLY B 111 THR B 116 -1 N GLY B 111 O THR B 167 SHEET 7 AA2 8 GLY B 196 SER B 199 -1 O GLY B 196 N LEU B 114 SHEET 8 AA2 8 PHE B 215 VAL B 216 -1 O PHE B 215 N TYR B 197 CRYST1 49.125 74.328 51.877 90.00 97.13 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.020356 0.000000 0.002546 0.00000 SCALE2 0.000000 0.013454 0.000000 0.00000 SCALE3 0.000000 0.000000 0.019427 0.00000